NASDAQ: CBUSCibus Inc Stock
$15.54+0.28 (+1.83%)
Updated Apr 25, 2024
CBUS Price
$15.54
Fair Value Price
-$2.30
Market Cap
$375.01M
52 Week Low
$8.90
52 Week High
$38.85
P/E
-0.6x
P/B
1.28x
P/S
111.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.82M
Earnings
-$267.63M
Gross Margin
100%
Operating Margin
-13,718.55%
Profit Margin
-14,729.1%
Debt to Equity
0.7
Operating Cash Flow
-$46M
Beta
1.17
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CBUS Overview
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CBUS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CBUS ($15.54) is overvalued by 775.31% relative to our estimate of its Fair Value price of -$2.30 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CBUS ($15.54) is not significantly undervalued (775.31%) relative to our estimate of its Fair Value price of -$2.30 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CBUS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CBUS due diligence checks available for Premium users.
Be the first to know about important CBUS news, forecast changes, insider trades & much more!
CBUS News
Valuation
CBUS fair value
Fair Value of CBUS stock based on Discounted Cash Flow (DCF)
Price
$15.54
Fair Value
-$2.30
Undervalued by
775.31%
CBUS ($15.54) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CBUS ($15.54) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CBUS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CBUS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.6x
Industry
15.41x
Market
40.97x
CBUS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.28x
Industry
5.8x
CBUS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CBUS's financial health
Profit margin
Revenue
$1.1M
Net Income
-$217.1M
Profit Margin
-19,684%
CBUS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CBUS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$544.4M
Liabilities
$206.1M
Debt to equity
0.7
CBUS's short-term assets ($35.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CBUS's long-term liabilities ($184.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CBUS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CBUS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.0M
Investing
-$449.0k
Financing
$18.3M
CBUS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CBUS vs Biotech Stocks
Cibus Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.